40% of a common but deadly type of brain tumor—called glioblastoma multiforme (GBM)—have mutations in a gene that encodes a protein called epidermal growth factor receptor (EGFR). These mutations result in hyper-activation of the protein.
A team led by Frank Furnari of the Ludwig Institute for Cancer Research at University of California, San Diego now finds that excessive EGFR signals ramp up expression of a protein called GBP1. Without GBP1, normally invasive GBM cells formed much less infiltrative tumors in the brains of mice.
GBP1 rendered tumors more invasive by triggering the production of MMP1, a protein that chops up the tissue around cells, allowing cancer cells to make inroads into healthy tissue. Additional work is needed to determine if therapies able to cripple GBP1 can contain GBM and impede its invasion into healthy tissue.
An abstract of the article can be found at http://jem.rupress.org/content/early/2011/12/08/jem.20111102.
About the Journal of Experimental Medicine
The Journal of Experimental Medicine (JEM) is published by The Rockefeller University Press. All editorial decisions on manuscripts submitted are made by active scientists in conjunction with our in-house scientific editors. JEM content is posted to PubMed Central, where it is available to the public for free six months after publication. Authors retain copyright of their published works and third parties may reuse the content for non-commercial purposes under a creative commons license. For more information, please visit http://www.jem.org.
Li, M., et al. 2011. J. Exp. Med. doi:10.1084/jem.20111102
Source: Rockefeller University Press Public release date: 12-Dec-2011